Home 2024

Archives

CorTec Brain Interchange Implant for Stroke Treatment

Stroke rehabilitation milestone, neurological conditions and future therapy

Martin Schuettler, Chief Technology Officer of CorTec GmbH, walks us through a groundbreaking achievement in the development of future therapies for neurological conditions like stroke.
High Energy Consuming Processes in Neurons: Axonal transport Synaptic vesicle recycling, Neurotransmitter release/reuptake, ion pumping, organelle maintenance, protein turnover. therapeutics for neurodegenerative disease

Contribution of oxidative stress to neurodegenerative disease

Paul A. Hyslop, from Arkley BioTek Indianapolis, details an ongoing specific research approach to identify, characterize, and validate physiologically relevant neuronal targets of H2O2 in designing therapeutics for neurodegenerative disease progression.
Neural cells network on a dark background - 3d rendered image of the neural cell network image on a black background. Glowing synapse. Displaying neurons and the neural network. Electrical impulses in neural networks.

Exploring HER-096: A novel approach to Parkinson’s Disease

Parkinson’s disease, a progressive neurodegenerative disorder, poses significant challenges for both patients and researchers. In a recent interview with Henri Huttunen from Herantis Pharma Plc, we delved into the intricacies of their potential novel disease-modifying therapy, HER-096.
Fig. 1 White matter hyperintensities (illustrated in blue) in a representative image of the human brain (A) are primarily found near ventricles. The neuronal cell bodies are found mainly in the cortex (gray matter) and myelinated neuronal axons in the white matter (B). Figure created using BioRender.

What is the link between white matter lesions and neurodegeneration?

Tara M. DeSilva from the Department of Neurosciences, Cleveland Clinic, examines the link between white matter lesions and neurodegeneration.
Figure 1: Immunomodulatory therapies are effective during the relapsing-remitting phase of MS, when immune cells are found in active lesions, but fail to ameliorate progressive decline and irreversible clinical disability. Increased axonal injury correlates with lack of immune cell infiltration but sustained activation of resident CNS glial cells in the progressive phase. These pathological findings are consistent with MRI imaging studies demonstrating virtually no new lesions occurring during progressive MS. Additionally, at the time of MS diagnosis there is evidence of prior lesion activity by MRI imaging supporting that the future development of neuroprotective strategies should be administered in combination with immunomodulatory therapies.

Targeting the central nervous system: The future of therapeutic strategies for MS

Tara M. DeSilva from the Department of Neurosciences, Cleveland Clinic, looks at the future of therapeutic strategies for MS, focusing on targeting the central nervous system.
White brain on white background with copy space - 3D illustration

How brain research is making the benefits of regular exercise accessible to all

Robert Wessells from Wayne State University looks to the brain to understand how the benefits of regular exercise can be delivered to those who are unable to move as easily.
Brain activity,Human brain damage,Neural network,Artificial intelligence and idea concept

Progress in development of disease-modifying treatments in Parkinson’s Disease

Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc, charts progress in the development of disease-modifying treatments for Parkinson’s disease.

Peroxisomes, lipids, and neurodegeneration

Prof. Michael Schrader at the University of Exeter looks to understand the role of peroxisomes in human health and disease.
image showing tanycytes in purple and the neurons they interact with in the hypothalamus (yellow: appetite promoting neurons expressing neuropeptide Y (NPY); blue: appetite suppressing neurons expressing the propopiomelanocortin (POMC))

The WATCH project: Tanycytes in health and disease

The WATCH project aims to elucidate how tanycytes mediate physiological processes by acting as gatekeepers between the brain and body, how their dysfunction is involved in various disorders and age-related impairments, and what can be done to prevent or correct these.
old Chinese couple using computer sat at dining table with mugs

Who benefits more from the cognitive effects of B vitamins?

Further understanding of the characteristics of the responders may shed light on how B vitamins benefit brain health and the formulation of more effective forms of B vitamins.
memory decline

Alzheimer’s drug slows memory decline in phase 3 trial

Henry Scowcroft from Alzheimer’s Research UK, argues that an Alzheimer’s drug, lecanemab, can slow memory decline in a phase 3 trial.

Follow Us

Advertisements

Open Access Government

Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.

Follow Us

Resources

Quick Links

Legal & Marketing

As a Crossref Sponsored Member we are able to connect your content with a global network of online scholarly research, currently over 20,000 other organizational members from 160 countries. Crossref drive metadata exchange and support nearly 2 billion monthly API queries, facilitating global research communication.

© Adjacent Digital Politics Ltd